Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys

Brain Research
D A Di MonteJ W Langston

Abstract

The effects of monoamine oxidase (MAO) inhibitors on the metabolism of dopamine synthesized from exogenous L-DOPA were investigated in the striatum and substantia nigra of squirrel monkeys. Administration of a single dose of L-DOPA (methyl ester, 40 mg/kg, i.p.) caused a significant increase in the levels of dopamine, 3-4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) and in the DOPAC/dopamine ratio in the putamen, caudate and substantia nigra. These changes were more pronounced in the substantia nigra than in the striatum and within the striatum of L-DOPA-treated monkeys, levels of dopamine and its metabolites were higher in the putamen than in the caudate nucleus. When L-DOPA treatment was preceded by the injection of clorgyline or deprenyl at a concentration (1 mg/kg) which selectively inhibited MAO A or MAO B, respectively, striatal dopamine was increased while the striatal DOPAC and HVA levels and DOPAC/dopamine ratio were significantly reduced as compared to the values obtained with 1-DOPA alone. The two MAO inhibitors also counteracted the increase in the DOPAC and HVA levels and DOPAC/dopamine ratio induced by L-DOPA in the substantia nigra. Thus, both MAO A and MAO B contribute to the metabolism of dopa...Continue Reading

References

Jan 6, 1977·Nature·V GloverG J Riley
May 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·R MoratallaA M Graybiel
Feb 1, 1992·Experimental Neurology·N J Riachi, S I Harik
Nov 16, 1989·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Oct 11, 1985·Science·K N WestlundC W Abell
Oct 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·P LevittX O Breakefield
Jan 1, 1980·Journal of Neural Transmission·C J FowlerB Winblad

❮ Previous
Next ❯

Citations

Jun 22, 2006·Neurotoxicity Research·T Archer, A Fredriksson
Apr 10, 2007·Journal of Neural Transmission·J P M Finberg, O Sader-Mazbar
Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jacobus P PetzerCornelis J Van der Schyf
Sep 10, 2002·Parkinsonism & Related Disorders·Christian PiflOleh Hornykiewicz
Jul 2, 2008·Parkinsonism & Related Disorders·P FoleyP Riederer
May 10, 2001·Proceedings of the National Academy of Sciences of the United States of America·G S De Zutter, R J Davis
Feb 24, 2015·Bioorganic & Medicinal Chemistry Letters·Zhanna V ChirkovaKyrill Yu Suponitsky
Oct 16, 2012·Bioorganic Chemistry·Lesetja J LegoabeJacobus P Petzer
Jun 19, 2012·Bioorganic & Medicinal Chemistry·Thokozile OkaecweJacobus P Petzer
Feb 9, 2012·European Journal of Medicinal Chemistry·Lesetja J LegoabeJacobus P Petzer
May 31, 2011·European Journal of Medicinal Chemistry·Belinda StrydomJacobus P Petzer
Jan 23, 2010·Bioorganic & Medicinal Chemistry·Belinda StrydomJacobus P Petzer
Feb 7, 2009·Journal of Neurochemistry·Martin LundbladIngrid Strömberg
Dec 10, 2013·The Journal of Pharmacy and Pharmacology·Anél PetzerJacobus P Petzer
Oct 12, 2011·Journal of Neurochemistry·Zhe WangJanis M O'Donnell
May 24, 2014·Expert Review of Neurotherapeutics·Cristian Follmer
Aug 2, 2012·Bioorganic & Medicinal Chemistry Letters·Lesetja J LegoabeJacobus P Petzer
Sep 19, 2009·The Journal of Medical Investigation : JMI· YinhuaYutaka Nakaya
Nov 6, 2012·Bioorganic & Medicinal Chemistry Letters·Mietha M Van der WaltJacobus P Petzer
Aug 10, 2013·Bioorganic & Medicinal Chemistry Letters·Rossella FioravantiMatilde Yáñez
Jul 23, 2011·Bioorganic & Medicinal Chemistry·Clarina I Manley-KingJacobus P Petzer
Dec 8, 2010·Bioorganic & Medicinal Chemistry·Clarina I Manley-KingJacobus P Petzer
Sep 10, 2013·Bioorganic & Medicinal Chemistry Letters·Letitia MeiringAnél Petzer
Feb 5, 2013·Bioorganic & Medicinal Chemistry Letters·Belinda StrydomJacobus P Petzer
Nov 8, 2011·Bioorganic & Medicinal Chemistry·Hermanus P BooysenJacobus P Petzer
Nov 22, 2011·Bioorganic Chemistry·Clarina I Manley-KingJacobus P Petzer
May 6, 2014·Bioorganic & Medicinal Chemistry Letters·Lesetja J LegoabeJacobus P Petzer
Aug 29, 2012·Neurochemical Research·Sofie C LangeMichael D Norenberg
Aug 2, 2017·Metabolic Brain Disease·Anzelle DelportJacobus P Petzer
Jul 14, 2017·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Qingcong WeiQigang Wang
Oct 16, 2009·Neuroscience and Behavioral Physiology·E L Dovedova
Oct 21, 2017·Brain : a Journal of Neurology·Junchao TongStephen J Kish

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.